Dolutegravir for younger children: results from the ODYSSEY trial
20 August 2019. Related: Early access, Conference reports, Paediatric care.
Early access
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
15 August 2019. Related: Early access, Conference reports, Antiretrovirals, Treatment strategies, Side effects.
High efficacy from switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance
1 August 2019. Related: Early access, Conference reports, Antiretrovirals.
Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution
1 August 2019. Related: Early access, Conference reports, Treatment strategies.
Cabotegravir/rilpivirine long-acting injectable HIV drugs submitted to EMA
1 August 2019. Related: Early access, Antiretrovirals.
Featured 29 March 2019: vol 20 no 4 – second CROI reports
28 March 2019. Related: Editorial, Early access.